Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.
Risa Wong, MD, hematology/oncology fellow at the University of Washington, reviews the standard treatment options for patients with metastatic urothelial cancer (mUC).
Patients with mUC who are defined as fit, are treated with first-line platinum-based combination chemotherapy as standard of care, explain Wong. In the past, after patients subsequently progressed, there were very limited options for subsequent therapy, and providers ended up retreating many of these patients with chemotherapy, either rechallenging them with a platinum-based regimen or switching to a nonplatinum-based chemotherapy regimen.
In recent years, there have been many advances in the treatment landscape and these patients can now receive immune checkpoint inhibitors.